Zoetis Inc

Most Recent

  • uploads///ASH
    Basic Materials

    Must-know: Why Maverick adds new position in Ashland

    Ashland has seen pressure from activist investor JANA Partners, which acquired a stake in the chemical maker in April, 2013, to boost shareholder value.

    By Samantha Nielson
  • uploads///PSH
    Fund Managers

    4Q14 Updates to Pershing Square Holdings

    Pershing Square Holdings filed its fourth quarter 13F last month. The fund’s US long portfolio rose to $16.04 billion, from $13.4 billion in 4Q14.

    By Samantha Nielson
  • uploads///thermometer _
    Earnings Report

    Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance

    Eli Lilly and Co. reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Merial Contributes to Sanofi’s Growth

    Merial, Sanofi’s (SNY) Animal Health segment, reported total revenues of 725 million euros (about $818.6 million), which is a 9.1% increase over 2Q15.

    By Mike Benson
  • uploads///Animal Health Segment
    Earnings Report

    How Did Merial Contribute to Sanofi’s 2Q15 Growth?

    Merial reported total revenues of 691 million euros, a 14.2% increase at constant exchange rates over 2Q14.

    By Mike Benson
  • uploads///Pershing
    Financials

    Pershing Square takes on Zoetis, adds to Canadian Pacific in 3Q14

    Activist hedge fund manager William Ackman’s Pershing Square Capital Holdings filed its third quarter 13F last month. The fund’s year-to-date returns as of October 31, 2014, net of fees, was 35.0%.

    By Samantha Nielson
  • uploads///Zoetis Business Model
    Financials

    Zoetis: An attractive business model

    Zoetis said in a recent statement that “its unique characteristics have established the company as the world leader in animal health, growing revenue faster than the market for the last three years.”

    By Samantha Nielson
  • uploads///ZTS industry stats
    Consumer

    Must-know trends that drive Zoetis’ growth

    Demand for Zoetis’ products is driven by a growing population coupled with a rising middle class in emerging markets and increased relocation from rural to urban areas.

    By Samantha Nielson
  • uploads///MSB issuance
    Financials

    Pershing Square adds to positions in Freddie Mac and Fannie Mae

    Pershing Square Management added more shares in mortgage financiers Freddie Mac (FMCC) and Fannie Mae (FNMA) during the drop in stock prices in October.

    By Samantha Nielson
  • uploads///Align technolgies
    Company & Industry Overviews

    Align Technology Stock Recovers after Tanking Last Week

    Align Technology stock (ALGN) took a massive hit after Q2 earnings. So what was behind the massive decline, and what’s helping the stock recover?

    By Sushree Mohanty
  • uploads///Graph
    Company & Industry Overviews

    What Are the Major Risks Affecting Elanco Animal Health?

    In its fourth-quarter earnings conference call, Elanco Animal Health (ELAN) reported a 4% YoY drop in sales driven by a 9% decline in sales volumes.

    By Margaret Patrick
  • uploads///FI
    Company & Industry Overviews

    Henry Schein to Merge Animal Health with Vets First Choice

    On April 23, Henry Schein (HSIC) announced its plans to spin off and merge its animal health business with Vets First Choice to form a joint venture, Vets First Corp.

    By Daniel Collins
  • uploads///Petmed Risks
    Company & Industry Overviews

    Key Risks Facing PetMed Express in 2017

    PetMed Express (PETS) stock has risen 77% in the last one-year period, reaching a high of $50.06 on July 26, 2017.

    By Kenneth Smith
  • uploads///PetMed Revenue growth
    Company & Industry Overviews

    New Customer Acquisition Drives Revenue Growth for PetMed Express

    In 2017, the PetMed Express (PETS) website attracted ~32.0 million visitors, ~8.0% of whom placed an order for a conversion ratio of ~25.0%.

    By Kenneth Smith
  • uploads///Part
    Company & Industry Overviews

    Analysts’ Recommendations for PetMed Express and Peers in 2017

    Of the five analysts covering PetMed Express (PETS) in October 2017, two gave it “strong buy” ratings, two gave it “hold” ratings, and one gave it a “sell” rating. Its target price was $43.75.

    By Kenneth Smith
  • uploads///Chart  AHR
    Company & Industry Overviews

    Behind Merck’s Animal Health Segment Performance in 2Q17

    Merck’s (MRK) Animal Health segment includes drugs and vaccines for animals and has operations spread across more than 140 countries worldwide.

    By Mike Benson
  • uploads///Chart  SWR
    Company & Industry Overviews

    Inside Merck’s Segment-Wise Performance in 2Q17

    Merck’s Pharmaceuticals segment contributed ~88.2% of total revenues in 2Q17, reporting $8.76 billion.

    By Mike Benson
  • uploads///Chart  MA
    Miscellaneous

    US Pharmaceuticals: Mergers and Acquisitions in 2Q17

    The US pharmaceutical sector comprises different setups pertaining to the development, manufacturing, production, and marketing of drugs. Let’s look at its performance in 2Q17.

    By Mike Benson
  • uploads///Chart  ZTS
    Miscellaneous

    Performance of Zoetis Stock in 2Q17

    Zoetis (ZTS) stock has risen ~17.3% in 2Q17, while it has risen ~15.4% year-to-date as of July 7, 2017.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    What’s Really Driving Zoetis’s Margins in 2017?

    Zoetis (ZTS) expects to generate savings of over $300 million in 2017 through its operational efficiency program.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Zoetis’s Apoquel and Cytopoint Are Expected to Report Robust Revenues

    In 1Q17, Zoetis’s (ZTS) dermatology portfolio reported revenues of ~$57 million, driven by the steady adoption of Cytopoint and Apoquel.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Why Zoetis Expects to See Robust Revenue Growth in 2017

    Zoetis (ZTS) has adopted a targeted R&D strategy that has resulted in multiple new product launches.

    By Margaret Patrick
  • uploads///Chart  Animal
    Earnings Report

    Performance of Eli Lilly & Co.’s Elanco in 1Q17

    Eli Lilly & Co.’s (LLY) Animal Health company, Elanco, reported an increase of 2% in revenues to $769.4 million in 1Q17, compared to $754.6 million in 1Q16.

    By Mike Benson
  • uploads///Chart  Animal
    Earnings Report

    Eli Lilly’s 1Q17 Estimates for Elanco

    Eli Lilly’s (LLY) animal health segment, Elanco, deals with products for companion animals as well as food and other products.

    By Mike Benson
  • uploads///Chart  Animal
    Company & Industry Overviews

    How Eli Lilly’s Elanco Performed in 2016

    Eli Lilly’s (LLY) Animal Health segment’s company, Elanco, reported a fall of 1% in its revenue to $3.16 billion in 2016, compared to $3.18 billion in 2015.

    By Mike Benson
  • uploads///Chart  Animal
    Earnings Report

    What to Expect from Eli Lilly’s Elanco in 4Q16

    Eli Lily’s US animal health revenues are expected to remain nearly constant during 4Q16.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Word on the Street about Merck’s Animal Health Segment

    Merck & Co.’s (MRK) Animal Health segment operates in more than 140 countries worldwide. Global sales for the segment are expected to rise to $915 million in 3Q16.

    By Mike Benson
  • uploads///Business Model
    Company & Industry Overviews

    Mylan’s Business Model: A Key Investor Rundown

    In 2014, Mylan earned about 85% of its total revenues from the US generic market, which is the largest generic market in the world.

    By Seth Richards
  • uploads///established pharmaceutical business
    Company & Industry Overviews

    A Key Look at Abbott Laboratories’ Acquisitions and Divestments

    Inorganic growth through acquisitions has led to the expansion of Abbott Laboratories across geographies and to the broadening of its product portfolio.

    By Sarah Collins
  • uploads///Segmentwise Revenues
    Earnings Report

    Changes in Merck & Co.’s Reported Business Segments in 2015

    The Global Human Health, or Pharmaceuticals, segment generates the most revenue for Merck. It contributed nearly 85% of the total revenue in 2014.

    By Mike Benson
  • uploads///KP
    Earnings Report

    Merck: Other Human Health Franchise and Animal Health Segment

    The animal health segment contributed ~8% of the total revenue in 2014. This contribution rose to ~9% for 2Q15 due to a rise in revenue by 10%.

    By Mike Benson
  • uploads///ZTS
    Fund Managers

    Highfields Capital Adds Zoetis to Its 4Q14 Portfolio

    Zoetis (ZTS) is the animal health business that Pfizer (PFE) spun off in June 2013.

    By Stuart McKenzie
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.